The Global Market for AIDS/HIV Testing and Treatment
The global HIV/AIDS market, including branded products and generics, was valued at $11.3 billion in 2010. This market is expected to reach $11.8 billion in 2011 and increase at a 4.6% compound annual growth rate (CAGR) over the 2011-2016 forecast period to reach $14.1 billion in 2016.
SCOPE OF REPORT
This report summarizes knowledge of HIV/AIDS and discusses the present status and evolution of the global AIDS epidemic, with analyses by selected major national markets. Latest treatment and diagnostic options and practices are described and their cost implications clarified, especially in the context of treatment affordability in countries of widely varying economic status. The emergence of a considerable generic medicine component in the marketplace, alongside the presence of original branded medicines, is discussed; profiles of both originator companies and generic suppliers are included and the role of governmental and charitable agencies explained. The current market for AIDS therapies is analyzed with breakdowns by major country and 5-year forecasts. Finally, major ongoing research is summarized and promising directions identified.
MARKET ANALYSES AND FORECASTS
Market figures are based on revenues at the manufacturer level and are projected at 2011 dollar value without attempting to predict the effect of inflation/deflation.
National market analyses and forecasts are provided for seven economically advanced countries and for five countries classified as of low to medium economic advancement.
Paul Evers has been involved in analyzing pharmaceutical and medical markets for 20 years. He is the author of previous reports on the HIV/AIDS marketplace as well as analyses of major therapeutic categories and the pharmaceutical regulatory environment.